PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2020; 12(02): 118-122
DOI: 10.4103/ijmbs.ijmbs_36_20
Original Article

Demographic characteristics and clinical manifestations of systemic sclerosis in Benghazi, Libya

Fathi Elbraky
1   Department of Internal Medicine, Faculty of Medicine, Benghazi University, Benghazi
,
Imhamed Amailaf
1   Department of Internal Medicine, Faculty of Medicine, Benghazi University, Benghazi
,
Khaled Alsaeiti
2   Department of Internal Medicine, Aljamhorya Hospital, Benghazi
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Background: Systemic sclerosis (SSc) is a rare, heterogeneous autoimmune disease characterized by skin fibrosis, vasculopathy, and internal organ involvement. This study aims to determine the frequency of clinical manifestations of SSc among Libyan patients in Benghazi. Patients and Methods: Thirty patients (28 females) attended the Rheumatology Clinic at Benghazi Medical Center between January 2016 and December 2019. They were diagnosed to have SSc according to American College of Rheumatology/European League Against Rheumatism 2013 revised classification criteria and were classified into diffuse cutaneous systemic sclerosis (dcSSc) and localized systemic sclerosis (lcSSc) disease subsets. Results: We reviewed the data of the 30 patients, including 28 (93.3%) females and 2 (6.7%) males (female: male ratio 14:1); the mean age at diagnosis was 40.5 ± 21.5 years (17–62 years). Twenty-four (80%) patients were diagnosed as dcSSc, whereas 6 (20%) were diagnosed as lcSSc. On diagnosis, patients with dcSSc were comparatively younger than those with lcSSc. The frequency of musculoskeletal manifestations and organ involvement was more frequent among patients with dcSSc (P = 0.001). All the thirty patients had rheumatoid factor and anti-nuclear antibody positivity. Anti-Scl-70 was only positive in the dcSSC subset in all patients of dcSSc only, whereas anti-centromere Ab was positive in all patients of lcSSc only. Conclusions: This is the first study to assess the clinical manifestations of SSc in the Libyan population. Our disease cohort showed similarity to what was published in other cohorts with regard to the age at the time of diagnosis, gender, and autoimmune profile.

Key-words:

Benghazi - diffuse - epidemiology - Libya - localized - rheumatology - systemic sclerosis

Financial support and sponsorship

Nil.




Publication History

Received: 02 April 2020

Accepted: 14 June 2020

Article published online:
07 July 2022

© 2020. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Semenov V, Kuryata O, Lysunets T. Clinical pattern of systemic sclerosis in Central Ukraine. Association between clinical manifestations of systemic sclerosis and hypertension. Reumatologia 2018;56:24-30.
  • 2 Derrett-Smith EC, Denton CP. Systemic sclerosis: Clinical features and management. Medicine 2010;38:109-15.
  • 3 Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011;7:e1002178.
  • 4 Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 2010;24:857-69.
  • 5 Silman AJ, Epidemiology of scleroderma. Ann Rheum Dis. 1991;50 Suppl 4(Suppl 4):846-53
  • 6 van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
  • 7 LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
  • 8 El Basel M, Khalil N. Disease characteristics of systemic sclerosis among Egyptian patients. Kasr Al Ainy Med J 2015;21:41-6
  • 9 Ben Salah R, Frikha F, Hachicha H, Chabchoub I, Dammak C, Snoussi M, et al. Clinical and serological profile of systemic sclerosis in Tunisia: A retrospective observational study. Presse Med 2019;48:e284-e291.
  • 10 Adelowo OO, Oguntona S. Scleroderma (systemic sclerosis) among Nigerians. Clin Rheumatol 2009;28:1121-5.
  • 11 Akakpo A, Teclessou J, Mouhari-Touré A, Saka B, Matakloe H, Kakpovi K, et al. Les sclérodermies en milieu hospitalier à Lomé: Étude de 50 cas. Médecine et Santé Tropicales 2017;27:446-8.
  • 12 Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
  • 13 Qaradakhy, T.A., Ali, K.M. & Karim, O.H. Prevalence of interstitial lung disease among patients with systemic sclerosis in Iraqi Kurdistan. Arthritis Res Ther 14, P13 (2012). https://doi.org/10.1186/ar3614
  • 14 Alam F, Abdulaziz HM, Ul Haq I, Mahdy SM, Mohammed Siam AR, Chandra P, et al. Characteristics of patients with systemic sclerosis living in Qatar. Qatar Med J 2019;2019:16.
  • 15 Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology (Oxford) 1999;38:397-400.
  • 16 Pagalavan L, Ong SG. Demography, clinical and laboratory features of systemic sclerosis in a Malaysian rheumatology centre. Med J Malaysia 2007;62:117-21.
  • 17 Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283:366-71.
  • 18 Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012;22:272-9.
  • 19 Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, et al., Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death. Medicine 2015;94:e1728.
  • 20 Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: A population-based cohort study. Arthritis Rheum 2005;52:2415-24.
  • 21 Ilovi S, Oyoo GJ. Characteristics of systemic sclerosis patients in Nairobi, Kenya: A retrospective study. Afr J Rheum 2013;1:8-12.
  • 22 Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 2007;66:754-63.
  • 23 Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA, et al., Epidemiology of Systemic Sclerosis in Northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34(5):714-720,
  • 24 Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, et al. The registry of the German network for systemic scleroderma: Frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008;47:1185-92.
  • 25 Aka B, Diabaté A, Kaloga M, Kourouma H, Vagamon B, Gue IJ. Scleroderma in a black African subject: A study of 217 cases in Cote d'Ivoire. J Clin Exp Dermatol Res 2017;8:2.
  • 26 Skare TL, Fonseca AE, Luciano AC, Azevedo PM. Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil. An Bras Dermatol 2011;86:1075-81.
  • 27 Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: Correlation with characteristic clinical features. Arthritis Res Ther 2011;13:R172.
  • 28 Pradhan V, Rajadhyaksha A, Nadkar M, Pandit P, Surve P, Lecerf M, et al. Clinical and autoimmune profile of scleroderma patients from Western India. Int J Rheumatol 2014;2014:983781.
  • 29 Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr., et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:358-67.
  • 30 Müller Cde S, Paiva Edos S, Azevedo VF, Radominski SC, Lima Filho JH. Autoantibody profile and clinical correlation in a group of patients with systemic sclerosis in southern Brazil. Rev Bras Reumatol 2011;51:314-8, 323-4.